A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention

New England Journal of Medicine

Volumn 373, Issue 17, 2015, Pages 1618-1626

  Chen, Andrew C ^a,b,c   Martin, Andrew J ^a   Choy, Bonita ^f   Fernandez Penas, Pablo ^f   Dalziell, Robyn A ^a   McKenzie, Catriona A ^b   Scolyer, Richard A ^b,c,f   Dhillon, Haryana M ^e   Vardy, Janette L ^d,e,g   Kricker, Anne ^f   George, Gayathri St ^f   Chinniah, Niranthari ^f   Halliday, Gary M ^a,c   Damian, Diona L ^a,c,f  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b Department of Tissue Pathology and Diagnostic Oncology ^*  (Australia)

^c Central Clinical School   (Australia)

^d Centre for Education and Research on Ageing Concord Clinical School   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE; PLACEBO; VITAMIN B COMPLEX;

ACTINIC KERATOSIS; ADNEXAL CARCINOMA; ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; BASAL CELL CARCINOMA; BLADDER CANCER; CANCER PREVENTION; CANCER RECURRENCE; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUODENUM CARCINOMA; FEMALE; FEMALE GENITAL TRACT CANCER; HEART FAILURE; HEMATOMA; HIGH RISK PATIENT; HUMAN; LUNG CANCER; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NONHODGKIN LYMPHOMA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SQUAMOUS CELL CARCINOMA; THORAX PAIN; TREATMENT DURATION; TREATMENT WITHDRAWAL; VITAMIN SUPPLEMENTATION; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; KERATOSIS, ACTINIC; MIDDLE AGED; MULTICENTER STUDY; SECONDARY PREVENTION; SKIN NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; NIACINAMIDE; SECONDARY PREVENTION; SKIN NEOPLASMS; VITAMIN B COMPLEX;

EID: 84944898663     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1506197     Document Type: Article

References (37)

1. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166: 1069-80.
2. Fransen M, Karahalios A, Sharma N, English DR, Giles GG, Sinclair RD. Nonmelanoma skin cancer in Australia. Med J Aust 2012; 197: 565-8.
3. Cancer in Australia: An overview, 2006. Canberra, ACT: Australian Institute of Health and Welfare, 2007.
4. Guy GP Jr, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011. Am J Prev Med 2015; 48: 183-7.
5. Rubin AI, Chen EH, Ratner D. Basalcell carcinoma. N Engl J Med 2005; 353: 2262-9.
6. Alam M, Ratner D. Cutaneous squamous- cell carcinoma. N Engl J Med 2001; 344: 975-83.
7. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001; 63: 8-18.
8. Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: A randomised controlled trial. Lancet 1999; 354: 723-9.
9. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993; 329: 1147- 51.
10. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: Randomized trial follow-up. J Clin Oncol 2011; 29: 257-63.
11. Ismail F, Mitchell L, Casabonne D, et al. Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photoprotection and levels of skin cancer awareness. Br J Dermatol 2006; 155: 916-25.
12. Yarosh DB. DNA repair, immunosuppression, and skin cancer. Cutis 2004; 74: Suppl: 10-3.
13. Park J, Halliday GM, Surjana D, Damian DL. Nicotinamide prevents ultraviolet radiation-induced cellular energy loss. Photochem Photobiol 2010; 86: 942-8.
14. Surjana D, Halliday GM, Damian DL. Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in human keratinocytes and ex vivo skin. Carcinogenesis 2013; 34: 1144-9.
15. Thompson BC, Surjana D, Halliday GM, Damian DL. Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in primary melanocytes. Exp Dermatol 2014; 23: 509-11.
16. Kuchel JM, Barnetson RS, Halliday GM. Cyclobutane pyrimidine dimer formation is a molecular trigger for solarsimulated ultraviolet radiation-induced suppression of memory immunity in humans. Photochem Photobiol Sci 2005; 4: 577-82.
17. Damian DL, Patterson CRS, Stapelberg M, Park J, Barnetson RS, Halliday GM. UV radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. J Invest Dermatol 2008; 128: 447-54.
18. Yiasemides E, Sivapirabu G, Halliday GM, Park J, Damian DL. Oral nicotinamide protects against ultraviolet radiationinduced immunosuppression in humans. Carcinogenesis 2009; 30: 101-5.
19. Surjana D, Halliday GM, Martin AJ, Moloney FJ, Damian DL. Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. J Invest Dermatol 2012; 132: 1497-500.
20. LeBoit PE, Burg G, Weedon D, Sarasain A, eds. World Health Organization classification of tumours: pathology and genetics of tumours of the skin. Lyon, France: International Agency for Research on Cancer, 2006.
21. Liu D, Pitta M, Jiang H, et al. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: Evidence for improved neuronal bioenergetics and autophagy procession. Neurobiol Aging 2013; 34: 1564-80.
22. Tanno O, Ota Y, Kitamura N, Katsube T, Inoue S. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br J Dermatol 2000; 143: 524-31.
23. Elmets CA, Viner JL, Pentland AP, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: A randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2010; 102: 1835-44.
24. Li X, Wu XB, Chen Q. Statin use is not associated with reduced risk of skin cancer: A meta-analysis. Br J Cancer 2014; 110: 802-7.
25. Moon TE, Levine N, Cartmel B, et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: A randomized, double-blind, controlled trial. Cancer Epidemiol Biomarkers Prev 1997; 6: 949-56.
26. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318: 1633-7.
27. Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: A double-blind, placebocontrolled study. J Clin Oncol 1995; 13: 1933-8.
28. McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999; 140: 656-60.
29. George R, Weightman W, Russ GR, Bannister KM, Mathew TH. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002; 43: 269-73.
30. Marquez C, Bair SM, Smithberger E, Cherpelis BS, Glass LF. Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients. J Drugs Dermatol 2010; 9: 753-8.
31. Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, Wolf P. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: A randomised study. Lancet 2001; 357: 926-9.
32. Shuttleworth D, Marks R, Griffin PJ, Salaman JR. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med 1988; 68: 717-25.
33. Pietkiewicz P, Gornowicz-Porowska J, Bowszyc-Dmochowska M, et al. Discordant expression of desmoglein 2 and 3 at the mRNA and protein levels in nodular and superficial basal cell carcinoma revealed by immunohistochemistry and fluorescent in situ hybridization. Clin Exp Dermatol 2014; 39: 628-35.
34. Bastiaens MT, Hoefnagel JJ, Bruijn JA, Westendorp RG, Vermeer BJ, Bouwes Bavinck JN. Differences in age, site distribution, and sex between nodular and superficial basal cell carcinoma indicate different types of tumors. J Invest Dermatol 1998; 110: 880-4.
35. Knip M, Douek IF, Moore WP, et al. Safety of high-dose nicotinamide: A review. Diabetologia 2000; 43: 1337-45.
36. Chen AC, Damian DL. Nicotinamide and the skin. Australas J Dermatol 2014; 55: 169-75.
37. Ranchoff RE, Tomecki KJ. Niacin or niacinamide? Nicotinic acid or nicotinamide? What is the difference? J Am Acad Dermatol 1986; 15: 116-7.